Skip Navigation U.S. Department of Health and Human Services
Agency for Healthcare Research Quality
Archive print banner
Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

Table 12. Tumor Characteristics Predictive of Disease Response or Survival: Group 1B—DNA Factors Evaluated During Imatinib Therapy

Prognostic factor Studies indicating an association and quality Strength of association with tumor response Strength of association with survival
Cytogenetic response to imatinib Marin, Marktel, Szydlo, et al., 200368
(Quality 5/5)
Achieved at least a minor CR with I:
RR for PFS = 0.09 (CI 0.03-0.25, p<0.0001)

No cytogenetic response with I:
RR for OS = 1.94 (CI 1.22-3.01, p=0.0053)
Achieved at least a minor CR with I:
RR for OS = 0.13 (CI 0.05-0.39, p=0.0002)

No cytogenetic response with I:
RR for OS = 1.69 (CI 1.09-2.64, p=0.02)

Adjusted probabilities of OS at 8 years were 78% (CI 51-93%) for responders, 23% (CI 18-29%) for IFN refractory historical controls not getting I, and 6% (CI 2-17%) for non-responders
O'Dwyer, 200496
(Quality 2/5)
Relationship of MCR to hemotologic relapse:
No MCR: N= 77 26%
MCR: N = 64 3%
HR 0.193 (CI 0.042-0.883)
Rosti, 20048
(Quality 4/5)
  Achieved at least a MCR with I:
OS estimated from KM at 26 mo median f/u
No MCR = 92%
MCR = 97%
Silver, 200483
  AP: Relationship between MCR at 3 mo and 3-yr survival:
MCR at 3 mo - 85% 3-yr OS
No MCR - 52% 3-yr OS

CP: Relationship between at least a MinorCR at 6 mos and 3-yr survival:
MinorCR at 6 mo - 96% 3-yr OS
No MinorCR at 6 mo - 86% 3-yr OS
Karntarjian, Cortes, et al., 200472
(Quality 5/6)
Relationship between Major or Minor CR and 4-yr PFS:
CR = 93%
No CR = 55%

Relationship between Major CR at 6 mo and 4-yr PFS:
CR = 94%
No CR = 51%
Relationship between MCR or MinorCR and 4-yr OS:
CR = 95%
No CR = 72%

Relationship between MCR or MinorCR at 6 mo and 4-yr OS:
CR = 96%
No CR = 70%

In multivariate analysis, MinorCR or MCR at 3 and 6 mo predict survival (p=0.03 and 0.01, respectively).
*Guilhot, 200462
CP-new diagnosis
Relationship between MCR at 6 mo and 30-mo PFS:
MCR at 6 mo (n=407) - 97%
No MCR at 6 mo (n=124) - 89%
Relationship between MCR at 6 mo and 30-mo OS:
MCR at 6 mo (n=407) - 97%
No MCR at 6 mo (n=124) - 92%
Marin, Marktel, Bua, et al., 200375
(Quality 2/5)
Relationship to PFS (described in terms of % of Ph+ metaphases at 3 months):
Ph+ 0-65% (Minor CR + MCR): N= 52 83%
Ph+ > 65% (No CR): N = 88 32%
Relationship to OS:
Ph+ 0-65%: N= 52 96%
Ph+ >65%: N = 88 52%
Change in CD34+ cells in the bone marrow *Marin, 2004100
Degree of reduction of CD34+ cells—RR for PFS = 0.88
(CI 0.53-0.93)

Abbreviations: * = abstract; AP = Accelerated phase; BP = Blastic phase; CI = 95% confidence interval; CP = Chronic phase; f/u = followup; HR = Hazard Ratio; I = Imatinib; IFN = Interferon; IFN-r = IFN refractory; K-M = Kaplan-Meier; OS = overall survival; EFS = event-free survival; M = Male; MCR = major molecular response; minorCR = minor molecular response; OS= Overall Survival; PFS = progression-free survival; pt(s) = patient(s); RR = relative risk

Return to Document
Proceed to Table 13

The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care